IN2014CN03925A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03925A
IN2014CN03925A IN3925CHN2014A IN2014CN03925A IN 2014CN03925 A IN2014CN03925 A IN 2014CN03925A IN 3925CHN2014 A IN3925CHN2014 A IN 3925CHN2014A IN 2014CN03925 A IN2014CN03925 A IN 2014CN03925A
Authority
IN
India
Prior art keywords
chimeric protein
dengue virus
create
virus
protein
Prior art date
Application number
Inventor
Sharon Isern
Scott F Michael
Original Assignee
Florida Gulf Coast University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Gulf Coast University filed Critical Florida Gulf Coast University
Publication of IN2014CN03925A publication Critical patent/IN2014CN03925A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related flavivirus) can be replaced by the corresponding portion from the dengue virus envelope protein. In some embodiments the chimeric protein may be used to create a treatment composition for DENV infection. In others the chimeric protein may be used to create a vaccine that will induce broadly protective antibodies against dengue virus and reduce the induction of non neutralizing antibodies that will cause enhancement.
IN3925CHN2014 2011-10-25 2012-10-25 IN2014CN03925A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550982P 2011-10-25 2011-10-25
PCT/US2012/061893 WO2013063248A1 (en) 2011-10-25 2012-10-25 Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes

Publications (1)

Publication Number Publication Date
IN2014CN03925A true IN2014CN03925A (en) 2015-07-03

Family

ID=48168485

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3925CHN2014 IN2014CN03925A (en) 2011-10-25 2012-10-25

Country Status (9)

Country Link
US (2) US20150265694A1 (en)
EP (1) EP2771366A4 (en)
CN (1) CN104736568A (en)
BR (1) BR112014009887A2 (en)
CR (1) CR20140189S (en)
HK (2) HK1198770A1 (en)
IN (1) IN2014CN03925A (en)
SG (1) SG11201401733VA (en)
WO (1) WO2013063248A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863695C (en) 2012-02-16 2023-01-17 Vlp Therapeutics, Llc Virus like particle composition
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
EP3191589A4 (en) * 2014-09-11 2018-05-09 VLP Therapeutics, LLC Flavivirus virus like particle
CN105732777B (en) * 2016-05-05 2019-06-04 中国人民解放军军事医学科学院微生物流行病研究所 Yellow fever virus specific detection antigen and its application
US11793873B2 (en) * 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
CN110343172B (en) * 2018-04-04 2021-09-03 中国科学院微生物研究所 High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof
CN109627294B (en) * 2018-12-29 2020-10-09 四川大学 Correctly folded recombinant rabies virus G protein extracellular domain and potential application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
KR100921592B1 (en) * 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 Chimeric flavivirus vectors
ZA200802176B (en) * 2005-08-10 2009-08-26 Acambis Inc Vaccination against dengue virus infection

Also Published As

Publication number Publication date
CN104736568A (en) 2015-06-24
BR112014009887A2 (en) 2017-04-25
EP2771366A1 (en) 2014-09-03
HK1206366A1 (en) 2016-01-08
EP2771366A4 (en) 2015-06-03
HK1198770A1 (en) 2015-07-31
US20150265694A1 (en) 2015-09-24
WO2013063248A1 (en) 2013-05-02
US10124053B2 (en) 2018-11-13
US20170202945A1 (en) 2017-07-20
SG11201401733VA (en) 2014-09-26
CR20140189S (en) 2014-09-24

Similar Documents

Publication Publication Date Title
IN2014CN03925A (en)
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
UA116087C2 (en) Methods for treating hcv
MX346264B (en) Anti-viral compounds.
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
EA029939B8 (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
MX358099B (en) Human immunodeficiency virus neutralizing antibodies adn methods of use thereof.
EA201270616A1 (en) HEPATITIS C VIRUS INHIBITORS
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
IN2014CN03113A (en)
PH12015502230A1 (en) Novel viral replication inhibitors
PH12014502628B1 (en) Compositions and methods related to the prevention and treatment of rabies infection
MX2013012233A (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines.
PH12015501076A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
CL2012000783A1 (en) Process to improve the effectiveness of protection method to induce an immune response against dengue virus comprising DNA vaccines and chimeric viruses 17d; vaccine composition comprising DNA vaccines against the four serotypes of dengue virus and chimeric viruses comprising the yellow fever vaccine virus; recombinant plasmid containing the gene for protein e.
MX360831B (en) Influenza c virus and vaccine.
WO2014201027A3 (en) Treatment of merkel cell polyomavirus infection
BR112013007308A2 (en) vaccine
MY164064A (en) Anti-viral compounds
MY171384A (en) Composition and methods related to the prevention and treatment of rabies infection
TN2013000453A1 (en) Hepatitis c virus inhibitors
MX358496B (en) Yeast-based therapeutic for chronic hepatitis b infection.
UA67522U (en) Method for enhancement of museum strain aurococcus atcc 25923 sensitivity to cefatoxim